The European Medicines Agency’s advisory group CHMP has adopted a negative opinion against approval for Novartis’ (NYSE:NVS) Revolade (eltrombopag) for treatment-naive patients at least two years old with severe aplastic anemia.
Revolade is currently approved in the EU for adults with severe aplastic anemia, HCV-positive adults with thrombocytopenia (low blood platelets) and patients at least one year old with immune thrombocytopenia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.